Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Random

Display 15 Products per page

Emricasan
Read More
Emricasan (Conatus/Novartis) is a small molecule which inhibits pan-caspases. These enzymes are key modulators of apoptosis and inflammation, and chronically elevated apoptosis is often present in liver disease, which leads to the accumulation of apoptotic cells and the release of apoptotic bodies. These end products of apoptosis are engulfed by surrounding tissues which promote disease pathology and inflammation.
July 22, 2019
Find out more
Molecular Diagnostics Market

$4,750.00

Molecular diagnostics is being applied to an increasingly wide range of applications in infectious disease, oncology, and genetic disease diagnosis and screening and to a number of emerging applications in other diseases. The global market for molecular diagnostics is expected to grow at a CAGR of 10.8% between 2019 and 2024, reaching a value of more than $12bn.
September 30, 2020
Find out more
Nimenrix
Read More
Nimenrix (quadrivalent polysaccharide tetanus toxoid conjugate vaccine; Pfizer) is a conjugated polysaccharide vaccine indicated for active immunization to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis (N. meningitidis) serogroups A, C, Y, and W-135 in individuals from the age of six weeks. It induces the production of bactericidal antibodies against capsular polysaccharides of N. meningitidis group A, C, W-135, and Y.
September 3, 2019
Find out more
Market Spotlight: Myelofibrosis (MF)

$1,318.00

This Market Spotlight report covers the Myelofibrosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
August 26, 2021
Find out more
Disease Analysis: Hepatitis C
Read More
Hepatitis C is a liver disease caused by chronic infection with hepatitis C virus (HCV), a hepacivirus belonging to the Flaviviridae family. HCV infects hepatocytes and is the leading cause of cirrhosis and hepatocellular cancer (HCC). Approximately 15−45% of people infected with HCV will spontaneously clear the virus, but the remaining 55−85% will develop chronic HCV infection. For those chronically infected with HCV, the risk of cirrhosis increases by 15–30% within 20 years.
October 8, 2021
Find out more
Germany, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure

$1,995.00

This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Germany; incidence and prevalence figures are compared with those of the Benelux countries
December 3, 2012
Find out more
M&A Analysis 2018

$3,000.00

PharmaVitae has launched the M&A Outlook 2018 report, click to view the 27 targets that potential acquirers should prioritize based on strategic themes, KOL interviews, and physician surveys.
April 24, 2018
Find out more
NASH KOL Insight Interview #1

$599.00

The prevalence data would suggest that in the US population about 30% of our population has fatty liver or NAFLD and of those 25% may have NASH and of those patients with NASH 25% percent may have fibrosis and progress to cirrhosis. It’s almost a pyramid effect, there may be 80 million Americans walking around with NAFLD, but to climb up to the top of the pyramid and develop cirrhosis would be about 5% of that total population, but that’s still significant because that would mean that the prevalence of cirrhosis [due to NASH] will exceed that of hepatitis C-related cirrhosis ten-fold
February 20, 2014
Find out more
Global Medical Technology & Device Markets Fact Book 2019

$2,995.00

This report provides a global view of key statistics of 165 technology markets around the world. Rich in stats, tables and graphs the report includes ranking tables for key performance indicators, economic, social and medical trade information, currency exchange impacts (US$ and local currency), and 10 year trend data for key sectors such as diagnostic imaging, disability products, medical/surgical consumables and orthopaedic products.
May 1, 2019
Find out more
Inhalation Drug Delivery Devices Market

$4,750.00

The combined prevalence of asthma and COPD in the countries covered by this report (US, Japan, and five major EU markets of France, Germany, Italy, Spain, and the UK) is 109.3 million. The combined market for inhalation drug delivery devices totaled nearly $11.7bn in 2016, and is expected to climb at a rate of 1.2% over the forecast period. Generic erosion will be a key factor in limiting growth in the overall market; however, increasing disease prevalence and the introduction of novel products such as triple combination therapies will offset declines. The US accounts for nearly two-thirds of the overall inhalation drug delivery devices market, and is expected to experience the most growth over the forecast period as its population increases and ages.
July 19, 2017
Find out more
Tivicay
Read More
Tivicay (dolutegravir; ViiV Healthcare) is a once-daily, unboosted integrase inhibitor (INI) for the treatment of HIV-1 infection.
June 28, 2019
Find out more
U.S. Markets for Heart Valve Disorder Management Products

$4,750.00

This comprehensive report examines the etiology and epidemiology, number of hospital discharges, incidence and prevalence, and mortality rates of the most prevalent diseases/disorders in the United States for the years 2000-2010, and 2013.
September 22, 2016
Find out more
Market Spotlight: Myelofibrosis

$1,318.00

This Market Spotlight report covers the Myelofibrosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
January 10, 2020
Find out more
United States, Cardiovascular Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

$1,995.00

This report presents the prevalence and number of hospital discharges in the UnitedStates (U.S.) as well as the surgical procedure volumes for selected cardiovascular/thoracic diseases/disorders.
January 1, 2013
Find out more
Ninlaro
Read More
Ninlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the accumulation of proteins and eventually leading to the activation of apoptotic pathways.
August 9, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *